Our discoveries- FGF inhibitors
Dobecure arises in summer 2017 as a tool to lead to the market the investigation developed all over the years from its scientific board members with the FGF inhibitors.
Based on the preclinical and clinical investigations, developed since the late 80’s, it has been developed the registration dossier of the FGF inhibitors for the treatment of both presentation means (dry and wet) of age-related macular degeneration (AMD).
Moreover, Dobecure continues with the preclinical and clinical studies in other disorders where the FGF might be involved.
Dr. Pedro Cuevas Sánchez
Head of Investigation
Chair of Cardiology
Universidad Alfonso X el Sabio
Dr. Luis Outeriño
Head of Ophtalmology Service Hospital Pio XII
Prof. Guillermo Giménez Gallego
Biological Investigations Centre
CESIC. – Spain
Rocío García Cañamaque
Clinical Research Expert
Funder – LeónResearch
Diego Cuevas Bourdier
Alfonso García Cañamaque
Provide an effective and safe treatment for those diseases that can be treated with inhibitors of fibroblast growth factor (anti-FGF) particularly in the inflammation and angiogenesis processes.
Out-licence those inhibitors and the clinical results for a better distribution in the global market, while contributing to treat diseases associated with inflammation and angiogenesis which prevalence affects more than 500 million people worldwide.
Continue investigating in new potential clinical uses for the synthetic inhibitors of fibroblast growth factor (FGF)
Investigate to cure.